20396 - Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09)

A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)

Disease Types: Breast,&nbs

Available at: {clinical_trial_location backspace="7"} 20396 - Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09), {/clinical_trial_location}

Principal Investigator: {clinical_trial_principle_investi} , {/clinical_trial_principle_investi}